Clearmind Medicine Files US Patent Application For Dyskinesia Treatment

Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.

Clearmind Medicine Inc (NASDAQ: CMND) has announced the filing of a provisional patent application for the treatment of Dyskinesia with the United States Patent and Trademark Office (USPTO) as part of its overarching strategy to strengthen its IP portfolio further.

The patent application refers to the psychedelic molecule 3-Methylmethcathinone (3-MMC) as a potential treatment for Dyskinesia and expands Clearmind’s portfolio for innovative molecules, new indications, and treatments. 

Dyskinesia is a category of movement disorders characterized by abnormal involuntary movements. It may manifest as chorea (irregular, involuntary movements of the body, especially the face, and extremities) or dystonia (disorder or lack of muscle tonicity). 

In addition, the patent application includes protection for its unique combination of 3-MMC and SciSparc’s Palmitoylethanolamide for Dyskinesia as part of its ongoing collaboration with SciSparc Ltd (NASDAQ: SPRC).

According to the WallStreet online, the patent application includes protection for its unique combination of 3-MMC and SciSparc’s Palmitoylethanolamide for the treatment of Dyskinesia, as part of its ongoing collaboration with SciSparc Ltd. (Nasdaq: SPRC) (“SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat central nervous system disorders.

“Clearmind continues to strengthen its position as a leader in the psychedelic-derived therapeutics industry through an aggressive strategy to expand our IP portfolio. Since our inception, 24 months ago, we have consistently extended our reach beyond MEAI, to additional second-generation psychedelic compounds,” said Clearmind’s Chief Executive Officer, Dr. Adi Zuloff-Shani. 

“There are several forms of Dyskinesia and various different causes including substance and alcohol withdrawal, and long-term use of medications, such as in Parkinson’s disease and other mental health disorders. Regardless of form or cause, it severely impairs patients’ daily functioning.  We believe our targeted treatments have the potential to bring relief to this underserved population.” said Dr. Adi Zuloff-Shani. 

Clearmind has a broad IP footprint in the psychedelic space, with 30 patents and patent applications across 14 patent families.

The company has already filed patent applications for the combination of Clearmind’s MEAI with SciSparc’s Palmitoylethanolamide for treating alcohol use disorder, cocaine addiction, and obesity, as well as related metabolic disorders.

Produced in association with Benzinga

Edited by Eunice Anyango Oyule and Judy J. Rotich